Quick Answer
A 2026 systematic review published in Global Advances in Integrative Medicine and Health screened the clinical literature on Ayurvedic management of primary insomnia in elderly patients. Of 11 studies meeting inclusion criteria (N=551 pooled), 10 reported improvements in sleep parameters - via external therapies (Shirodhara, Nasya, Netratarpana) and internal herbal agents (Tagara, Jatamansi, Ashwagandha). Tagara showed greater improvement in sleep onset latency and total sleep duration compared to Jatamansi. Ashwagandha was most effective when combined with Nasya therapy. The verdict is Promising: century-old Ayurvedic approaches have consistent clinical support, but heterogeneous study designs prevent definitive conclusions and well-designed trials with standardised protocols are still needed.
At a Glance
What this study looked at
Ayurvedic medicine has classified sleep - Nidra - as one of the three pillars of health for centuries, alongside food and celibacy. Its approach to sleep disruption is multi-modal: combining external therapies that act through the nervous system and sensory pathways, alongside internal herbal agents selected for their specific effects on body movement, mental activity, and arousal. The question this 2026 review asks is whether these traditional approaches hold up when evaluated against modern clinical standards, specifically in elderly patients where insomnia is both more prevalent and more complex to treat.
Kulkarni and colleagues, publishing in Global Advances in Integrative Medicine and Health, conducted a systematic review specifically targeting Ayurvedic clinical evidence for primary insomnia in geriatric cohorts. They screened the available literature and identified 11 studies meeting their inclusion criteria: 6 randomised controlled trials and 5 case series, covering 551 participants. The interventions reviewed fell into two broad categories - external therapies (applied directly to the body) and internal herbal agents - and included both monotherapy and combination approaches.
The focus on elderly patients is clinically significant. Insomnia in older adults tends to be more persistent, more structurally entrenched (involving changes to sleep architecture with age), and more complicated by polypharmacy and comorbidities. Non-pharmacological approaches are particularly attractive in this population because they avoid the dependency, cognitive impairment, and fall-risk concerns associated with sedative sleep medications.
Study Selection
The key findings
1. 10 of 11 studies reported sleep improvements
The headline result is consistent: 10 out of 11 studies reported improvements in at least some sleep parameters through Ayurvedic interventions, whether external, internal, or a combination of both. This positive signal cuts across a body of evidence that is heterogeneous in design, population, and outcome measurement - which makes the consistency notable.
The important caveat: while most studies reported "positive outcomes in relief," only 2 of the 11 used standardised, validated outcome measures such as the Insomnia Severity Index (ISI) or the Pittsburgh Sleep Quality Index (PSQI). The remaining 9 used symptom-based or clinician-assessed outcomes without validated scales. This makes it difficult to quantify the magnitude of improvement or compare results meaningfully across studies.
2. Tagara outperformed Jatamansi on sleep onset and total duration
When compared directly, Tagara (Valeriana wallichii) showed greater improvement in sleep onset latency and total sleep duration than Jatamansi (Nardostachys jatamansi). Both herbs are classified as nervous system relaxants in Ayurveda - but their profiles diverge on which dimension of sleep they most reliably affect.
Tagara is described in classical Ayurvedic texts as working to calm body movement and metabolism while relaxing the mind, making it particularly suited for fragmented and disturbed sleep. The modern pharmacological parallel is consistent: Tagara contains valerenic acid and related compounds that act on GABAergic and serotonergic pathways - mechanisms central to sleep initiation and continuity. This positions Tagara as an herb that targets the transition into sleep and its maintenance, rather than simply producing sedation.
3. Ashwagandha showed strongest effect combined with Nasya
Ashwagandha (Withania somnifera) showed the strongest sleep improvements in the included studies when used in combination with Nasya therapy - the nasal administration of medicated oils - rather than as a standalone agent. This combination effect is consistent with Ayurvedic pharmacology, which classifies Nasya as a brain-targeted route with the potential to enhance the CNS-relevant effects of simultaneously administered herbal agents.
Ashwagandha holds a dual classification in Ayurveda: as a Rasayana (a rejuvenating tonic that promotes vitality and longevity) and as a Nidrajanana (a sleep promoter, specifically in contexts of anxiety and depleted vital energy). The modern pharmacological understanding centres on cortisol modulation and HPA axis regulation - Ashwagandha has been shown to reduce cortisol levels and attenuate stress-driven physiological arousal, which is one of the root drivers of poor sleep quality in both younger and elderly populations.
4. External therapies showed consistent benefit across studies
Beyond the internal herbs, the three external therapies reviewed - Shirodhara, Nasya, and Netratarpana - each showed positive outcomes in the included studies. Shirodhara involves the continuous, gentle pouring of warm medicated oil over the forehead; it is proposed to act via the frontal cortex and the trigeminal nerve, inducing a parasympathetic state that reduces neural arousal. Netratarpana involves bathing the eyes in medicated ghee and is associated with sensory relaxation and reduced sympathetic activation.
These non-pharmacological external therapies are particularly relevant for elderly patients where minimising internal medication burden is a clinical priority. They represent a distinct therapeutic category from herbal supplementation and are less directly translatable to a daily home practice, but their consistent presence in the positive-outcome studies is worth noting.
| Intervention | Type | Reported sleep outcomes | Uses validated scale |
|---|---|---|---|
| Tagara (Valeriana wallichii) | Internal herb | Improved sleep onset latency, total sleep duration | In some studies |
| Ashwagandha + Nasya (combined) | Internal + external | Greatest sleep improvement; anxiety reduction | In some studies |
| Jatamansi (Nardostachys jatamansi) | Internal herb | Sleep improvements, but less than Tagara on onset and duration | Inconsistent |
| Shirodhara (medicated oil on forehead) | External therapy | Reduced arousal, improved sleep onset and quality | Inconsistent |
| Nasya (nasal administration) | External therapy | CNS calming; enhanced herb efficacy when combined | Inconsistent |
| Netratarpana (eye bath with ghee) | External therapy | Sensory relaxation, sympathetic nervous system calming | Inconsistent |
How these herbs work: the mechanism
Tagara: the sleep-onset and duration herb
Tagara is the Ayurvedic name for Valeriana wallichii, a species closely related to the European valerian (Valeriana officinalis) that has been studied extensively in Western sleep research. Its primary active constituents - valerenic acid, isovaleric acid, and a range of flavonoids - interact with GABA-A receptors in the brain, increasing GABAergic inhibitory tone. This makes it mechanistically distinct from sedatives, which flood GABA receptors to suppress neural activity broadly. Tagara's effect is more targeted: it supports the inhibitory pathway that allows the aroused nervous system to downregulate into a sleep-compatible state.
The Ayurvedic characterisation - calming body movement and metabolism, relaxing the mind, suitable for disturbed and fragmented sleep - maps closely onto this GABAergic mechanism. When the nervous system is running too fast to transition into sleep, or when sleep is repeatedly interrupted rather than simply delayed, GABA pathway support is directly relevant.
Ashwagandha: the stress-reset and cortisol-modulation herb
Ashwagandha's dual Ayurvedic classification as both Rasayana (rejuvenating) and Nidrajanana (sleep-promoting) reflects two distinct biological actions. Its primary modern pharmacological role is as an adaptogen: it supports the HPA axis (hypothalamic-pituitary-adrenal axis) in regulating the cortisol stress response. Elevated or dysregulated cortisol - particularly the pattern of cortisol remaining high or spiking in the evening when it should be declining - is one of the most common contributors to sleep onset difficulties and middle-of-the-night waking.
By supporting cortisol regulation and attenuating the physiological stress response, Ashwagandha addresses the arousal problem upstream, rather than directly sedating the nervous system. This explains why it showed the strongest effect in combination with Nasya - a therapy that acts directly on the brain via the nasal route. The combination addresses both the cortisol pathway (Ashwagandha internally) and the neural arousal pathway (Nasya externally), creating a complementary dual action.
"Ayurvedic management of primary insomnia in elderly patients holds promise, particularly via non-invasive therapies and herbal agents. Still, evidence is preliminary." - Kulkarni et al., Global Advances in Integrative Medicine and Health, 2026
Verdict: Promising
Ten of 11 Ayurvedic studies showed improvements in sleep parameters, with Tagara and Ashwagandha emerging as the herbs with the clearest clinical signal. The consistency across a heterogeneous body of evidence is notable, and the mechanistic logic for both herbs is well-supported by modern pharmacology. The limitations are real and significant: no meta-analysis was possible, only 2 of 11 studies used validated scales, and only 2 specifically targeted elderly patients. This is an early but coherent evidence base. Promising.
Study limitations
Limitations (editorial analysis)
What This Means Tonight
The practical takeaway
This systematic review does something unusual: it bridges centuries of Ayurvedic clinical practice with modern clinical trial methodology. The result is not a clean, quantified effect size - the evidence is too heterogeneous for that. What it does show is a consistent signal across 10 of 11 studies, spanning different Ayurvedic protocols and different populations, pointing toward genuine sleep benefit.
The two herbs that stand out - Tagara and Ashwagandha - each address a distinct dimension of the sleep problem. Tagara targets the transition into sleep and its continuity, working through GABAergic pathways that support the nervous system's shift from aroused to settled. Ashwagandha targets the upstream stress response: by supporting cortisol regulation, it addresses the physiological state that keeps many people awake not because they are not tired, but because their biology has not received a clear signal that it is safe to rest.
These are not mechanisms that produce sedation. They support the conditions under which natural sleep becomes more accessible. For people whose sleep problems are driven by an overactive, stress-elevated nervous system that does not switch off at night - rather than a simple difficulty feeling tired - this distinction matters.
The evidence is promising, not established. Well-designed trials with larger cohorts, standardised diagnostic tools, and consistent outcome measures are needed to confirm these findings. But the signal from 2,000-plus years of Ayurvedic clinical observation, now beginning to accumulate in peer-reviewed literature, points consistently in the same direction.
From Our Formula
Reincarn Night Reboot™ contains both herbs featured in this review: Tagara Root Extract (300mg per sachet) and KSM-66 Ashwagandha (300mg per sachet). These are the two internal agents with the clearest clinical signal in the Kulkarni et al. 2026 systematic review.
Tagara is included to support sleep initiation and continuity by calming sympathetic nervous system activity, working via GABAergic pathways that help the body transition into and maintain sleep. KSM-66 Ashwagandha is included as the Stress Reset ingredient in the formula: shown in clinical studies to reduce stress and cortisol levels, it addresses the arousal pathway that keeps the nervous system elevated at night. In Reincarn Night Reboot™, these two herbs work alongside Magnesium Bisglycinate, Glycine, L-Theanine, Maizinol UP165, and Vitamin B6 (P5P) to support the full sleep cycle. Individual ingredients have been tested in clinical studies; the 7-ingredient formula has not been tested together in a single trial.
Contains Tagara 300mg + KSM-66 Ashwagandha 300mg per sachet
Reincarn Night Reboot™: the Ayurvedic herbs, clinically dosed, alongside five more.
REINCARN Reincarn Night Reboot™ is melatonin-free and formulated with both Tagara Root Extract (300mg) and KSM-66 Ashwagandha (300mg) - the two herbs with the strongest signal in this systematic review - alongside Magnesium Bisglycinate, Glycine, L-Theanine, patented Maizinol UP165, and Vitamin B6 (P5P). Seven ingredients. Seven pathways. One recovery window.
Order Reincarn Night Reboot™Publisher's Note
This issue covers the Kulkarni et al. 2026 systematic review of Ayurvedic interventions for insomnia because it provides clinical context for two ingredients in Reincarn Night Reboot™: Tagara (300mg per sachet) and KSM-66 Ashwagandha (300mg per sachet). We have a commercial interest in presenting these ingredients favourably, and we disclose it. The verdict here is Promising, not Established. The evidence base has real limitations - heterogeneous designs, absence of validated scales in most studies, and sparse elderly-specific data. We report these honestly because our readers deserve an accurate read of the science, not a promotional summary. This Digest issue is published by Zandra Life Sciences Pvt. Ltd., the maker of REINCARN Reincarn Night Reboot™.
Every issue, one paper. No noise.
The Sleep Performance Digest covers one peer-reviewed paper per issue - chosen for study design, journal quality, and relevance to sleep recovery. Published when the science warrants it.
Frequently Asked Questions
Do Ayurvedic herbs help with insomnia?
A 2026 systematic review of 11 Ayurvedic clinical studies (N=551) found that 10 of 11 reported improvements in sleep parameters through Ayurvedic interventions. The evidence base is heterogeneous and most studies did not use validated sleep scales, so the conclusion is Promising rather than Established. The most consistent clinical signal came from Tagara (for sleep onset and duration) and Ashwagandha (especially when combined with Nasya therapy).
What is Tagara and how does it support sleep?
Tagara (Valeriana wallichii) is an Ayurvedic herb classified as a nervous system relaxant. In the 2026 Kulkarni et al. review, it showed greater improvement in sleep onset latency and total sleep duration than Jatamansi. Its active compounds interact with GABA and serotonin pathways, supporting the nervous system's transition from an aroused to a sleep-compatible state. It is distinct from sedatives: it supports the downregulation process rather than forcing shutdown.
What is the evidence for Ashwagandha and sleep?
Ashwagandha is classified in Ayurveda as both a rejuvenating tonic (Rasayana) and a sleep promoter (Nidrajanana). In the 2026 review, it showed the strongest sleep improvements when combined with Nasya therapy. Its primary modern pharmacological role is cortisol modulation: it supports HPA axis regulation and reduces physiological stress arousal - one of the root drivers of difficulty falling and staying asleep. KSM-66 Ashwagandha has been shown in clinical studies to reduce stress and cortisol levels.
Are Ayurvedic sleep interventions safe for elderly people?
The 2026 systematic review did not find reports of serious adverse events in the included studies, but the authors flagged a significant gap: most studies did not systematically report adverse events at all. This means the safety profile cannot be fully characterised from the current evidence base. The absence of adverse event reporting is itself a methodological limitation. Elderly individuals, particularly those on multiple medications, should consult a healthcare professional before using any herbal supplement.
What are the limitations of this research?
The key limitations are: no meta-analysis was possible due to heterogeneous study designs; only 2 of 11 studies used validated sleep outcome scales (ISI or PSQI); most studies did not report adverse events; only 2 of 11 specifically targeted elderly patients; and multi-component Ayurvedic protocols make it difficult to attribute outcomes to individual interventions. The review's conclusion - Ayurvedic management of primary insomnia holds promise, but evidence is preliminary - accurately reflects the current state of this literature.
Does Reincarn Night Reboot™ contain Tagara and Ashwagandha?
Yes. Reincarn Night Reboot™ contains Tagara Root Extract (300mg per sachet) and KSM-66 Ashwagandha (300mg per sachet) - both herbs with the strongest clinical signal in this systematic review. These are two of the seven ingredients in the Reincarn Night Reboot™ formula, which also includes Magnesium Bisglycinate, Glycine, L-Theanine, Maizinol UP165, and Vitamin B6 (P5P). Individual ingredients have been tested in clinical studies; the combined 7-ingredient formula has not been tested together in a single trial.
References
- Kulkarni et al. (2026). Ayurvedic Interventions for Primary Insomnia in the Elderly: A Systematic Review of Clinical Evidence and Research Gaps. Global Advances in Integrative Medicine and Health, Volume 15: 1-12. DOI: 10.1177/27536130261440317. PMID: 42694495. PubMed
- Langade D et al. (2019). Efficacy and Safety of Ashwagandha (Withania somnifera) Root Extract in Insomnia and Anxiety: A Double-blind, Randomized, Placebo-controlled Study. Cureus. 11(9):e5797.
- Chandrasekhar K et al. (2012). A Prospective, Randomized Double-Blind, Placebo-Controlled Study of Safety and Efficacy of a High-Concentration Full-Spectrum Extract of Ashwagandha Root in Reducing Stress and Anxiety in Adults. Indian Journal of Psychological Medicine. 34(3):255-262.
- Bent S et al. (2006). Valerian for Sleep: A Systematic Review and Meta-Analysis. American Journal of Medicine. 119(12):1005-1012.
- Donelli D et al. (2019). Effects of ashwagandha (Withania somnifera) on stress and the stress-related neuropsychiatric disorders anxiety, depression, and insomnia. Phytotherapy Research. 33(12):3166-3177.